<DOC>
	<DOCNO>NCT02683018</DOCNO>
	<brief_summary>The use cannabis severe medical condition legalize different state , increase mandate make cannabis legal medically ill patient . However , lack placebo-controlled study investigate efficacy cannabis . Dronabinol ( synthetic , oral Δ-9-THC ) FDA approve appetite stimulation AIDS-related anorexia nausea/vomiting chemotherapy patient . Nabilone , synthetic analogue THC , approve nausea/vomiting chemotherapy patient . These medication find effective disorder , remain interest study cannabis , partly due numerous cannabinoids contain within cannabis plant . Among cannabidiol , produce subjective effect , show potent anti-inflammatory effect . In addition , data indicate cannabidiol may effective neuropathic pain nausea/vomiting . The goal investigate effect high CBD/low THC cannabis symptom pain , nausea/vomiting , quality life seriously ill participant . While data begin emerge cannabis may beneficial effect symptom , placebo control , double-blind study . Additionally , administration cannabis medically ill patient may limited subjective effect , anxiety , intoxication , paranoia . Most cannabis available today high level Δ-9-THC ( 15 % ) . By use cannabis high CBD , low - Δ-9-THC , hypothesize effect avoid , maximize therapeutic effect , .</brief_summary>
	<brief_title>Investigation Cannabis Chronic Pain Palliative Care</brief_title>
	<detailed_description>The goal study perform double-blind , placebo-controlled study investigate efficacy cannabis , compare placebo , medically ill participant seek relief symptom pain , nausea , vomit . Participants meet criterion severe condition refer clinician . Cannabis high concentration cannabidiol , cannabinoid change perception produce intoxication , low Δ-9-THC use . In way , hope maximize benefit cannabis , lower possible side effect cannabis medically ill participant . The overall goal study compare active high cannabidiol ( CBD ) / low ( − ) -trans-Δ9- tetrahydrocannabinol ( THC ) cannabis v placebo cannabis patient serious medical disorder . Participants refer clinician come laboratory daily ( 3-5 time weekly ) cannabis ( 15.76 % CBD ; 3.11 % Δ-9-THC ) v placebo ( 0.0 % CBD/ 0.01 % Δ-9-THC ) . The cannabis vaporize smoked cannabis cigarette . The participant choose option prefer . The cross-over design use participant receive 2 week active cannabis vs two week placebo counterbalance order , participant blind condition . The outcome measure primarily include measure pain , secondary measure mood , nausea/appetite , quality life , potentially positive negative subjective effect cannabis ( e.g. , high , mellow , anxious , paranoid ) .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>1 . One medical diagnosis ( cancer , amyotrophic lateral sclerosis , Parkinson 's disease , spinal cord injury , neuropathy , phantom limb pain , thalamic pain , pain related injury nerve plexus/plexi , neuropathic facial pain ) , report pain ( least 3 item 3 9 item Brief Pain Inventory ) remain despite current medical treatment . 2 . Age 2160 3 . Able give inform consent , comply study procedures 4 . Experience inhale substance . 1 . Meet DSMV criterion current major psychiatric illness , bipolar disorder , major depression , active suicidality , psychosis , could exacerbate administration cannabis 2 . Meet criterion major neurological disorder , mild cognitive impairment neurodegenerative disorder ( movement disorder , dementia ) , could exacerbate administration cannabis . 3 . Women practice effective form birth control ( condom , diaphragm , birth control pill , IUD ) currently pregnant 4 . Current ( weekly ) use cannabis 5 . Participants supplemental oxygen 6 . Participants substance use disorder involve marijuana opioids .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>